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Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths
around the globe. For patients receiving liver tumour resection, the risk of reoccurrence and
metastasis is high. Cancer metastasis can occur as a consequence of a physical change
known as epithelial to mesenchymal transition (EMT). In this instance, cancer cells acquire
migratory and invasive characteristics that allow the cells to move into adjacent tissue or
enter the bloodstream to reach a secondary site, where they begin to form a new tumour.
Targetting proteins involved in the signalling pathways that induce the mesenchymal phe-
notype has been an ongoing field of research. A recently published study has described
a novel role for the heart development protein with EGF-like domains (HEG1) in promot-
ing EMT. This research provides new insights into the biological function of this protein in
HCC. Furthermore, the research indicates a new target for future prognostic and therapeutic
research in HCC.
The poor survival rate of hepatocellular carcinoma (HCC) is largely due to late-stage diagnoses and re-
occurrence or metastasis of tumours. Although liver transplants are the most effective means of increasing
survival rates, the limited availability of organ donors and the strict criteria for eligible HCC recipients
results in most early-stage patients receiving resection [1,2]. Resection of HCC tumours have a high risk
of reoccurrence and/or metastasis due to incomplete resection or de novo tumour formation [2]. Intra-
hepatic and extrahepatic metastasis can be attributed to de-differentiation of epithelial liver cancer cells
into a mesenchymal phenotype. Known as the epithelial to mesenchymal transition (EMT), this process
involves loss of epithelial markers, such as E-cadherin and the α- and γ-catenins, and increased expres-
sion of mesenchymal markers, such as N-cadherin and α-smooth muscle actin (αSMA), to promote local
and microvascular invasion. Many pathways have been characterized in stimulating EMT, most notably
is the potent action of transforming growth factor (TGF-β), which regulates the Wnt/β-catenin pathway
to induce EMT and metastasis [3]. Activation of TGF-β/Wnt signalling is also associated with early HCC
reoccurrence and poor patient survival [4]. Although these pathways have been identified in HCC pa-
tient subpopulations, finding reliable EMT biomarkers and therapeutic targets is still an ongoing field of
research.
A recent published work by Zhao and colleagues [5] have described a novel function for the heart
development protein with EGF-like domains (HEG1) in HCC. Although HEG1 is relatively understudied,
its primary role is involved in cardiac development and endothelial cell junction formation [6,7]. Previous
work has also implicated HEG1 as a highly specific marker for malignant mesothelioma [8]. In the more
recent study, Zhao and colleagues [5] have elegantly described the function of HEG1 in HCC invasion
and metastasis through the action of β-catenin to activate Wnt signalling and induce EMT.
The Wnt signalling pathway has been well described and normally serves important functions in em-
bryonic development. Specifically, the Wnt/β-catenin pathway regulates the expression of genes involved
in cell proliferation, cell survival and cell differentiation. In a series of events, Wnt ligands bind to a cell
surface receptor, known as frizzled (FZD), which freesβ-catenin from a repression complex [9].β-catenin
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Figure 1. HEG1 signalling in EMT
HEG1 stabilizes β-catenin and promotes localization to the nucleus. β-catenin induces expression of genes involved in activating
EMT and promotes HCC metastasis. Abbreviations: APC, adenomatosis polyposis coli; HEG, heart development protein with
EGF-like domain; MMP, matrix metallopeptidase; P, phosphate; ZEB1, zinc finger E-Box binding homeobox 1.
then accumulates in the cytoplasm and is translocated to the nucleus to act as a co-transcription factor for various
genes involved in regulating cell behaviour [9]. Zhao and colleagues [5] have described a novel function for HEG1
as a protein that interacts with and stabilizes cytosolic β-catenin, while increasing translocation to the nucleus. Fur-
thermore, the authors demonstrated that HEG1 may down-regulate the expression of adenomatosis polyposis coli
(APC), which acts to repress β-catenin accumulation and target it for degradation (Figure 1) [5]. Previous studies
have only implicated HEG1 as a transmembrane receptor protein [7,8]. However, the more recent study described
HEG1 as localizing to the cytoplasm to interact with β-catenin [5]. The limiting number of studies regarding HEG1
function make it difficult to evaluate exactly how HEG1 localizes and functions within a cell, or within a cancer cell
setting. However, previous work has suggested HEG1 to have similar structure and function to membrane-associated
mucin proteins (MUC) [8]. Localization of MUC can occur in the membrane or the cytosol and is variable in malig-
nant cancers, and high MUC expression has been associated with increased cancer metastasis [10]. It is probable that
HEG1 functions similar to MUC in hepatic cancer, but more research is required to validate this highly specific role
of HEG1 in cancer progression.
In addition, the authors of the present study have identified a close link with HEG1 expression and invasive mes-
enchymal HCC cell behaviour. They demonstrated that HCC cells overexpressing HEG1 had greater migratory ca-
pabilities in vitro. Furthermore, orthotopic xenograft models showed significantly greater incidences of intrahep-
atic and lung metastasis in tumour models with HEG1 overexpression [5]. This observation was further validated
with functional analyses, demonstrating that HEG1 expression correlated with genes involved in EMT. More specif-
ically, increased HEG1 expression correlated with loss of E-cadherin, which is an essential cell adhesion molecule
required for maintaining normal epithelial cell interactions [5,10]. HEG1 expression also increased expression of the
mesenchymal marker vimentin, which is in turn a significant component of the intermediate filaments required for
mesenchymal cell integrity [11]. Low expression of E-cadherin and high expression of vimentin have previously been
associated with a prognostic signature, along with high expression of mucin 1 (MUC1), for predicting poor prog-
nosis in HCC [10]. Considering the structural and functional similarities between HEG1 and MUC1 [8], it may be
concluded that a similar signature may be derived involving HEG1, E-cadherin and vimentin for predicting HCC
patient outcome. As demonstrated by Zhao and colleagues [5], analyses of HEG1 expression in HCC patients further
supports the prognostic value of this novel protein.
The present study used two patient cohorts totalling over 230 HCC samples to show a positive association with
HEG1 expression and HCC prognosis. Patients with high HEG1 expression showed a distinct profile of larger tu-
mours with vascular invasion and more advanced tumour node metastasis (TNM) and Barcelona Clinic Liver Cancer
(BCLC) stages compared those with low HEG1 expression [5]. Furthermore, high HEG1 expression was significantly
associated with decreased overall survival (OS) and disease-free survival (DFS) in both cohorts and was an indepen-
dent risk factor for both shorter OS and DFS [5]. These data demonstrate compelling evidence of HEG1 as a specific
marker of metastatic potential and poor prognosis in HCC. Typically, liver tumour specimens are examined for more
classical prognostic factors such as BCLC or TNM tumour staging, or molecular factors including vascular invasion
and α-fetoprotein levels. A combination of these factors often provides sufficient evidence to determine likelihood of
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tumour reoccurrence. However, due to the complex nature of HCC, the tumour classification systems are not glob-
ally standardized and determining vascular invasion can be difficult to distinguish between the normal vasculature
[12,13]. Measuring HEG1 expression quantitatively from a small piece of tissue or through histological analysis may
be a simpler indication of metastatic activity. However, using HEG1 expression as a prognostic marker would also
require standardizing a minimum expression level for poor prognosis indication. Nonetheless, the use of HEG1 as an
addition to the current methods of evaluating patient prognosis may be valuable if validated further.
With this newfound biological understanding of HEG1 function in HCC cancer cells, Zhao and colleagues [5]
suggest HEG1 may serve as a valuable therapeutic target. The authors demonstrated that HEG1 knockdown signif-
icantly reduced HCC cell invasion and metastasis in vitro and in vivo, by preventing EMT through up-regulation
of APC [5]. While the authors show compelling evidence of the significant role of HEG1 in activating EMT, it is
questionable whether HEG1 will be an effective therapeutic target. Previously noted, EMT signalling pathways are
extensive, and there are many EMT triggers that may induce multiple pathways that could result in activating EMT.
Other studies have investigated many relevant proteins that may be involved in such signalling pathways. For ex-
ample, another study has shown that another membrane protein, metadherin (MTDH), has very similar effects on
inducing EMT and metastasis in HCC [14]. This work also found a strong correlation with high MTDH expression
and low E-cadherin expression, high vimentin and increased β-catenin localization to the nucleus. Furthermore, the
present study reported significant correlational analysis with high MTDH expression and poor patient prognosis in
HCC [14]. Both studies demonstrate mimicking results that indicate they can both independently activate Wnt sig-
nalling through β-catenin to activate EMT in HCC [5,14]. Whether or not HEG1 and MTDH function together to
induce metastasis warrants further study. Nonetheless, this demonstrates only one example of the various factors that
could contribute to metastasis in cancer progression. Targetting HEG1 as a therapeutic strategy to prevent metastatic
HCC may only benefit a unique subset of patients who have high expression of HEG1. Although the efficacy of this is
still contentious, considering it is likely that there are still many other active proteins within the heterogenic tumour
capable of inducing EMT transition. Anti-HEG1 therapy may be more beneficial as a component of a patient specific
anti-tumour drug cocktail delivered to target multiple relevant pathways catered to the patient in question.
The increasing incidence and poor survival rate of HCC remains a global issue, largely due to insufficient treatment
options. Although liver transplants and tumour resection are curative options, the rate of reoccurrence is high and
can be attributed to intrahepatic metastasis from primary tumour sites. The recent study by Zhao and colleagues [5]
has demonstrated exceptional evidence for a novel role of HEG1 in activating EMT to induce metastatic activity in
HCC. The clinical evidence describes a strong correlation with HEG1 expression and patient prognosis, suggesting
it may be a valuable prognostic marker. Targetting the EMT pathway has yet to be a successful strategy for treating
HCC patients, so it is unclear whether HEG1 would be an effective therapeutic target. Even so, the present study is the
first to define a function for HEG1 in HCC development, and provides a new avenue for future research in defining
EMT in cancer progression.
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